cannabidiol
cannabidiol: 10 clinical trials tracked.
cannabidiol evidence translation
What we can confirm
10 tracked trials
What it means
What to watch
Prepared research question
What is verified about cannabidiol, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence6 indications · 4 study sponsors
Related indications
Clinical Trials (10)
A Phase 3b/4, Interventional, Prospective, Multicenter, Open-Label Study Evaluating the Effectiveness of a Gradual Titration Regimen to Optimize CBD-OS as Add-On Therapy in Adults With Lennox-Gastaut Syndrome
Primary endpoint: Percentage of participants reporting 50% or more reduction in their 28-day average countable major motor seizure frequency
A Phase 2 Randomized, Multicenter Study of Non-Invasive Vagus Nerve Stimulation (nVNS), Cannabidiol, and Standard of Care for the Treatment of Persistent Post-Traumatic Headache in Elite Athletes
Primary endpoint: Moderate-severe headache days
ImPRoving OutcoMes in Individuals at Clinical High Risk fOr Psychosis Using Cannabidiol: a Double-blind, Randomised conTrollEd Trial
Primary endpoint: ChaChange from baseline in attenuated positive psychotic symptoms (CAARMS P1-P4 positive symptom subscale score)
Pathophysiological Mechanisms of Cannabidiol in Stress Regulation
Primary endpoint: Neural (BOLD) functional response
Adjunctive Cannabidiol for Recovery From Opioid Study (ACROS)
Primary endpoint: Percentage of study participants with negative urine toxicology for illicit opioid use
A Phase II, Blinded, Randomised, Placebo Controlled Clinical Trial to Determine the Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis
Primary endpoint: Change in pain and function
A Phase 4, Interventional, Multicenter, Open-Label, Single-Arm Study to Assess Behavioral and Other Co-occurring Outcomes Following Treatment With EPID(I/Y)OLEX as Add-on Therapy in Participants (Aged 1 to 65 Years Old) With Seizures Associated With Tuberous Sclerosis Complex
Primary endpoint: Change in the most problematic behavior Numerical Rating Score (NRS) score within the TAND-SQ
Cannabidiol Pharmacotherapy for Co-occurring Opioid Use Disorder and Chronic Pain
Primary endpoint: Primary Outcome Variable #1: Safety and tolerability of CBD
A Long-term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution
Primary endpoint: Number of Participants With Liver Fibrosis and Evaluable Fibrotic Changes as Determined and Assessed by an Independent Adjudication Committee
Neuroimaging and CBD for Opioid Use Disorder
Primary endpoint: CBD effects on in vivo glutamatergic levels within mesocorticolimbic brain regions